Seric IgG anti-SARS-CoV-2 pre- and post- Covid-19 pandemic from Mexican asymptomatic subjects
DOI:
https://doi.org/10.21149/12930Palabras clave:
igG anti-SARS-CoV-2, ELISA, asymptomatic subjects, donorsResumen
Objective. To detect serum IgG anti-SARS-CoV-2 in pre-and post- Covid-19 pandemic in Mexican asymptomatic subjects in order to know the degree of viral dispersion. Materials and methods. Association of serum IgG antibodies (determined by ELISA) to sociodemographic and clinical data or contact with Covid-19 cases in three groups of subjects: 1) Covid-19 pre-pandemic blood donors (n= 538); 2) Covid-19 post-pandemic blood donors (n= 243); 3) Covid-19 post-pandemic neurological patients (n= 312). None of the subjects studied had been vaccinated. Results. The positive rate of IgG anti-SARS-CoV-2 was notably higher in participants recruited during the pandemic (donors, 29.6%; neurological patients, 15.7%) than in those recruited pre-pandemic (donors 0.6%) (p <0.001). Other conditions associated to antibody positivity were being a worker in sales or services, or having had previous contact with people with Covid-19, for donnors and neurological patients, and having diabetes mellitus, for neurological patients. Higher positivity levels of anti-SARS-CoV-2 IgG were found in females than in males. The highest proportion of subjects with anti-SARS-CoV-2 antibodies was found in central Mexico. Conclusions. The dispersion of SARS-CoV-2 in asymptomatic, unvaccinated subjects (donors and neurological patients) recruited in a Mexican health institution, who work in sales or services or had previously had contact with Covid-19 patients is 16 to 30%. The level of positivity for anti-SARS-CoV-2 IgG is higher in females than in males. SARS-CoV-2 antibody seroprevalence follow-up studies must be favored among the general population, being mandatory for donors.
Descargas
Citas
Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group. BioRxiv [preprint]. 2020. https://doi.org/10.1101/2020.02.07.937862
Sun J, He WT, Wang L, Lai A, Ji X, Zhai X, et al. COVID-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med. 2020; 26(5):483-95. https://doi.org/10.1016/j.molmed.2020.02.008
Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. J Clin Med. 2020;9(4):1225. https://doi.org/10.3390/jcm9041225
Machhi J, Herskovitz J, Senan AM, Dutta D, Nath B, Oleynikov MD, et al. The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. J Neuroimmune Pharmacol. 2020;15(3):359-86. https://doi.org/10.1007/s11481-020-09944-5
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. https://doi.org/10.1056/nejmoa2001017
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-74. https://doi.org/10.1016/S0140-6736(20)30251-8
Meyer B, Drosten C, Müller MA. Serological assays for emerging coronaviruses: Challenges and pitfalls. Virus Res. 2014;194(1):175-83. https://doi.org/10.1016/j.virusres.2014.03.018
Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215(1):108427. https://doi.org/10.1016/j.clim.2020.108427
Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370(6522):1339-43. https://doi.org/10.1126/science.abe1107
Nguyen-Contant P, Embong AK, Kanagaiah P, Chaves FA, Yang H, Branche AR, et al. S protein-reactive IGG and memory B cell production after human SARS-CoV-2 infection includes broad reactivity to the S2 subunit. MBio. 2020;11(5):e01991-20. https://doi.org/10.1128/mBio.01991-20
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260-3. https://doi.org/10.1126/science.abb2507
Baloch S, Baloch MA, Zheng T, Pei X. The coronavirus disease 2019 (COVID-19) pandemic. Tohoku J Exp Med. 2020;250(4):278. https://doi.org/10.1620/tjem.250.271
World Health Organization. WHO COVID-19 Dashboard. Geneva: WHO, 2021.
Yang Y, Shang W, Rao X. Facing the COVID-19 outbreak: What should we know and what could we do? J Med Virol. 2020;92(6):536-7. https://doi.org/10.1002/jmv.25720
Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177-9. https://doi.org/10.1056/NEJMc2001737
Tu H, Tu S, Gao S, Shao A, Sheng J. Current epidemiological and clinical features of COVID-19; a global perspective from China. J Infect. 2020;81(1):1-9. https://doi.org/10.1016/j.jinf.2020.04.011
Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970-1. https://doi.org/10.1056/nejmc2001468
Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of Co¬vid-19 — studies needed. N Engl J Med. 2020;382(13):1194-6. https://doi.org/10.1056/nejmp2002125
Zhang L, Pang R, Xue X, Bao J, Ye S, Dai Y, et al. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging. 2020;12(8):6536-42. https://doi.org/10.18632/AGING.103102
Bao L, Deng W, Gao H, Xiao C, Liu Jiayi, Xue J, et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. BioRxiv [preprint]. 2020. https://doi.org/10.1101/2020.03.13.990226
Eckhardt CM, Cummings MJ, Rajagopalan KN, Borden S, Bitan ZC, Wolf A, et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(1):499. https://doi.org/10.1186/s13063-020-04422-y
Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38. https://doi.org/10.1038/nri.2016.90
Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: An overview. Eur J Pharmacol. 2020;889(1):17644. https://doi.org/10.1016/j.ejphar.2020.173644
Diario Oficial de la Nación. NOM-253-SSA1-2012 Para la disposición de sangre humana y sus componentes con fines terapéuticos. Mexico: Diario Oficial de la Federación de México, 2012.
McEnroe RJ, Durham AP, Goldford MD, Kondratovich MV, Lababidi S, Magari R, et al. Evaluation of precision of quantitative measurement procedures; approved guideline. PA, USA: Clinical and laboratory standards institute, 2014; 37-54.
Berte’ R, Mazza S, Stefanucci MR, Noviello D, Costa S, Ciafardini C, et al. Seroprevalence of SARS-CoV2 in IBD patients treated with biological therapy. J Crohn’s Colitis. 2021;15(5):864-8. https://doi.org/10.1093/ecco-jcc/jjaa237
Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383(18):1724-34. https://doi.org/10.1056/NEJMoa2026116
Papalini C, Paciosi F, Schiaroli E, Pierucci S, Busti C, Bozza S, et al. Seroprevalence of anti-SARS-CoV2 Antibodies in Umbrian Persons Living with HIV. Mediterranean J Hematol Infect Dis. 2020;12(1):e2020080. https://doi.org/10.4084/MJHID.2020.080
Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg Infect Dis. 2020;26(7):1478-88. https://doi.org/10.3201/eid2607.200841
Wec AZ, Wrapp D, Herbert AS, Maurer DP, Haslwanter D, Sakharkar M, et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science. 2020;369(6504):731-6. https://doi.org/10.1126/science.abc7424
Conti P, Younes A. Coronavirus cov-19/sars-cov-2 affects women less than men: Clinical response to viral infection. J Biol Regul Homeost Agents. 2020;34(2):339-43. https://doi.org/10.23812/Editorial-Conti-3
Bunders MJ, Altfeld M. Implications of sex differences in immunity for SARS-CoV-2 pathogenesis and design of therapeutic interventions. Immunity. 2020;53(3):487-95. https://doi.org/10.1016/j.immuni.2020.08.003
Barin B, Yoldascan BE, Savaskan F, Ozbalikci G, Karaderi T, Çakal H. Joint investigation of 2-month post-diagnosis IgG antibody levels and psychological measures for assessing longer term multi-faceted recovery among COVID-19 cases in Northern Cyprus. Front Public Health. 2021;8:590096. https://doi.org/10.3389/fpubh.2020.590096
Lei H, Xu X, Xiao S, Wu X, Shu Y. Household transmission of COVID-19-a systematic review and meta-analysis. J Infect. 2020;81(6):979-97. https://doi.org/10.1016/j.jinf.2020.08.033
Waterfield T, Watson C, Moore R, Ferris K, Tonry C, Watt A, et al. Seroprevalence of SARS-CoV-2 antibodies in children: A prospective multicentre cohort study. Arch Dis Child. 2021;106(7):680-6 https://doi.org/10.1136/archdischild-2020-320558
Mendoza RP, Fyke W, Daniel D, Gabutan E, Das B, Bajaj H, et al. Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes. Hum Immunol. 2021;82(4):255-63. https://doi.org/10.1016/j.humimm.2021.02.007
Ngo BT, Marik P, Kory P, Shapiro L, Thomadsen R, Iglesias J, et al. The time to offer treatments for COVID-19. Expert Opin Investig Drugs. 2021;30(5):505-18. https://doi.org/10.1080/13543784.2021.1901883
Diago-Sempere E, Bueno JL, Sancho-López A, Rubio EM, Torres F, de Molina RM, et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials. 2021;22(1):70. https://doi.org/10.1186/s13063-020-05011-9
Fernandez J, Gratacos-Ginès J, Olivas P, Costa M, Nieto S, Mateo D, et al. Plasma exchange: an effective rescue therapy in critically ill patients with coronavirus disease 2019 infection. Crit Care Med. 2020;48(12):e1350-5. https://doi.org/10.1097/CCM.0000000000004613
Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Ann Intern Med. 2020;173(5):362-7. https://doi.org/10.7326/M20-3012
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2022 Salud Pública de México
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Al proponer un trabajo para su publicación, los autores aceptan las condiciones contenidas en las presentes normas y ceden a Salud Pública de México los derechos patrimoniales sobre el artículo en cuestión, a fin de que ésta lo edite, publique, reproduzca, difunda, comercialice, traduzca o autorice su traducción a cualquier idioma.
Los derechos transferidos incluyen la publicación del artículo por cualquier medio, sea éste impreso, magnético o electrónico, o por cualquier otro soporte o medio de difusión que exista o pueda crearse en el futuro, así como la realización de publicaciones mediante la concesión de licencias totales o parciales a terceros.
Los artículos aceptados serán publicados en Salud Pública de México bajo una licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional.
Los trabajos propuestos deberán ser originales e inéditos, y no podrán presentarse a ninguna otra revista mientras se encuentren sometidos a la consideración de Salud Pública de México.También se reciben trabajos completos publicados previamente en forma de resumen, o trabajos no publicados presentados en congresos o seminarios.
Todos los trabajos serán publicados con pleno conocimiento de los autores.
Los artículos firmados son responsabilidad de los autores y no necesariamente reflejan la opinión de la revista, del Instituto Nacional de Salud Pública o de la institución a la que están afiliados los autores.
